肺炎克雷伯菌耐碳青霉烯类抗菌药的研究进展

肺炎克雷伯菌是一种常见的机会性致病菌，为医院内感染的重要病原菌之一。近年来，肺炎克雷伯菌的感染率及耐药率呈上升趋势，碳青霉烯类抗菌药是治疗该菌最有效的抗菌药物，但随着使用的增加，其耐药性也不断增加。本文就肺炎克雷伯菌对碳青霉烯类抗生素耐药的主要机制：产生碳青霉烯酶、青霉素结合蛋白对碳青霉烯类亲和力的下降、高产AmpC酶或ESBLs合并外膜蛋白缺失、生物被膜、主动外排系统等方面的研究进展作一综述。

Progress about Carbapenem Resistant of Klebsiella pneumoniae

Klebsiella pneumoniae is a common opportunistic pathogen and an important nosocomial pathogen. In recent years, with the rapidly increasing rate of infection and drug-resistance, carbapenems are the most potent agents prescribed for the treatment of serious infection caused by Klebsiella pneumoniae currently. However, the wide-spread use of carbapenems has led to the emergence of carbapenem-resistant isolates, which become an important therapeutic challenge. In this article, we researched some progresses about the mechanisms of carbapenemresistant Klebsiella pneumoniae （CR-KP）, which are as follows： the acquisition of carbapenemases, decreased affinity of penicillin-binding protein （PBS） for carbapenems, hyperproduction of AmpC cephalosporinases or extendedspectrum beta-lactamases （ESBLs） in combination with loss of the outer membrane protein, biofilm, effiux pump system.